Capital Research Global Investors’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $66.5M | Sell |
4,750,579
-14,558
| -0.3% | -$204K | 0.01% | 322 |
|
|
2025
Q1 | $64.8M | Sell |
4,765,137
-712,074
| -13% | -$9.68M | 0.01% | 339 |
|
|
2024
Q4 | $112M | Sell |
5,477,211
-2,431,903
| -31% | -$49.6M | 0.02% | 291 |
|
|
2024
Q3 | $230M | Buy |
7,909,114
+782,581
| +11% | +$22.8M | 0.05% | 201 |
|
|
2024
Q2 | $165M | Buy |
7,126,533
+1,076,576
| +18% | +$25M | 0.04% | 240 |
|
|
2024
Q1 | $124M | Buy |
6,049,957
+3,140,429
| +108% | +$64.4M | 0.03% | 271 |
|
|
2023
Q4 | $62.4M | Buy |
2,909,528
+29,205
| +1% | +$627K | 0.02% | 307 |
|
|
2023
Q3 | $59.4M | Buy |
2,880,323
+42,671
| +2% | +$880K | 0.02% | 315 |
|
|
2023
Q2 | $83.7M | Buy |
2,837,652
+368,828
| +15% | +$10.9M | 0.02% | 291 |
|
|
2023
Q1 | $56.9M | Buy |
2,468,824
+208,182
| +9% | +$4.8M | 0.02% | 316 |
|
|
2022
Q4 | $62.9M | Buy |
2,260,642
+2,172,875
| +2,476% | +$60.4M | 0.02% | 311 |
|
|
2022
Q3 | $2.65M | Buy |
+87,767
| New | +$2.65M | ﹤0.01% | 416 |
|